TY - JOUR
T1 - IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy
T2 - Clinical significance and diagnostic utility of a conventional assay
AU - Kadoya, Masato
AU - Kaida, Kenichi
AU - Koike, Haruki
AU - Takazaki, Hiroshi
AU - Ogata, Hidenori
AU - Moriguchi, Kota
AU - Shimizu, Jun
AU - Nagata, Eiichiro
AU - Takizawa, Shunya
AU - Chiba, Atsuro
AU - Yamasaki, Ryo
AU - Kira, Jun ichi
AU - Sobue, Gen
AU - Ikewaki, Katsunori
N1 - Funding Information:
This study was supported in part by a Health and Labour Sciences Research Grant on Rare and Intractable Diseases (Evidence-based Early Diagnosis and Treatment Strategies for Neuroimmunological Diseases; No. 16ek0109056h0103 ) from the Ministry of Health, Labour and Welfare of Japan .
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2016/12/15
Y1 - 2016/12/15
N2 - We aimed to validate the diagnostic utility of enzyme-linked immunosorbent assay (ELISA) for the detection of anti-neurofascin (NF) 155 antibody in 191 patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Human NF155-based ELISA clearly distinguished between anti-NF155 antibody-positive and -negative sera. Fifteen CIDP patients (8%) were IgG4 anti-human NF155 antibody-positive, which were confirmed by western blot, cell-based assay and immunohistochemical study. None of disease controls or healthy subjects had positive results. Clinical presentation of IgG4 anti-NF155 antibody-positive patients was consistent with those in previous reports. This ELISA combined with determination of the IgG4 subclass is useful in screening for anti-NF155 antibodies.
AB - We aimed to validate the diagnostic utility of enzyme-linked immunosorbent assay (ELISA) for the detection of anti-neurofascin (NF) 155 antibody in 191 patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Human NF155-based ELISA clearly distinguished between anti-NF155 antibody-positive and -negative sera. Fifteen CIDP patients (8%) were IgG4 anti-human NF155 antibody-positive, which were confirmed by western blot, cell-based assay and immunohistochemical study. None of disease controls or healthy subjects had positive results. Clinical presentation of IgG4 anti-NF155 antibody-positive patients was consistent with those in previous reports. This ELISA combined with determination of the IgG4 subclass is useful in screening for anti-NF155 antibodies.
UR - http://www.scopus.com/inward/record.url?scp=85001968724&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85001968724&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2016.10.013
DO - 10.1016/j.jneuroim.2016.10.013
M3 - Article
C2 - 27852440
AN - SCOPUS:85001968724
SN - 0165-5728
VL - 301
SP - 16
EP - 22
JO - Advances in Neuroimmunology
JF - Advances in Neuroimmunology
ER -
